Pfizer to Invest $600 Million in Biotechnology and Neuroscience

Pfizer Inc., plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture investment vehicle.

According to the company, Pfizer Ventures seeks to invest twenty-five percent of its available capital ($150 million) in “promising early-stage neuroscience companies.” By leveraging its equity investment model, Pfizer plans to support neuroscience research and product development opportunities in neurodegeneration, neuro-inflammation, and neuro-metabolic disorders. Six of Pfizer Ventures’ current portfolio company investments—Aquinnah, Autifony, Cortexyme, MindImmune, MISSION, and Neuronetics—focus on breakthrough neuroscience.

Pfizer Ventures also plans to continue to invest in therapeutic areas such as oncology, inflammation and immunology, rare disease, internal medicine, and vaccines.